Linker Information
General Information of This Linker
| Linker ID |
LIN0YVGZJ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Ser-Glu linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C10H15BrN2O7
|
|||||
| Isosmiles |
OC([C@H](CCC(O)=O)NC([C@H](CO)NC(CBr)=O)=O)=O
|
|||||
| InChI |
InChI=1S/C10H15BrN2O7/c11-3-7(15)12-6(4-14)9(18)13-5(10(19)20)1-2-8(16)17/h5-6,14H,1-4H2,(H,12,15)(H,13,18)(H,16,17)(H,19,20)/t5-,6-/m0/s1
|
|||||
| InChIKey |
AJTQMBPNSGANAO-WDSKDSINSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
355.141
|
Polar area
|
153.03
|
||
|
Complexity
|
356.2346001
|
xlogp Value
|
-1.7074
|
|||
|
Heavy Count
|
20
|
Rot Bonds
|
9
|
|||
|
Hbond acc
|
5
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
38283215 ADC 18 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.69 ug/mL
|
High TNF expression (TNF +++) | ||
| Method Description |
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.
Click to Show/Hide
|
||||
| In Vitro Model | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia | K562 cells (TNF) | CVCL_0004 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 20 ug/mL | Negative TNF expression (TNF-) | ||
| Method Description |
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.
Click to Show/Hide
|
||||
| In Vitro Model | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia | K562 cells (wt) | CVCL_0004 | ||
References